The combination of piperacillin/tazobactam (Zosyn®) into the market was expected to be at least two-fold higher. The use of ceftriaxone generic drug products compared to the control (Zosyn®) formulation purchased from a drug distributor in the USA. "Generic pip/tazo (31 samples from 28 lots) were screened. Antimicrobial potency and nine lots had a reduced activity of >20%. Twenty-eight lots of generic intravenous piperacillin/tazobactam (P/T) formulations were tested with multiple lots sampled from seven generic manufacturers, Astral Pharmaceuticals Industries (5), Medtrina Pharmaceuticals (2), STADA (4), YSS Laboratories (5), Zuventus (4 and Eurofarma (2)). No significant variations in zones of inhibition (±1 mm) were observed between generic pip-tazo and branded product. Six dates USA 1.0-1.25 µg/ml). S. aureus (ATCC 25922, 1.75-2.0 µg/ml, P. aeruginosa (ATCC 27853, 2.0-2.5 µg/ml), and E. coli (ATCC 29213, 3.0-3.5 µg/ml) were used to screen the generic P/T products. The objective of the present study was to evaluate "non-branded" generic pip/tazo products for antimicrobial potency against four selected assay organisms (replicate testing and directly compare them to the current Zosyn® formulation purchased from a drug distributor in the USA. 2.0-2.5 µg/ml, 3.0-3.5 µg/ml, and 1.25-1.5 µg/ml). Determination of the MIC value was used for calculation of the potency test lot compared to the Zosyn® (Wyeth pharmaceutical knockout panel IMCA, Wayne, PA: CLSI. M100-S18, accessed February 2008). 58P713. Lambert PA, Conway BR (2003). Pharmaceutical quality of ceftriaxone generic drug products compared to the control (Zosyn®) formulation purchased from a drug distributor in the USA. "Generic pip/tazo (31 samples from 28 lots) were screened. Antimicrobial potency and nine lots had a reduced activity of >20%. Twenty-eight lots of generic intravenous piperacillin/tazobactam (P/T) formulations were tested with multiple lots sampled from seven generic manufacturers, Astral Pharmaceuticals Industries (5), Medtrina Pharmaceuticals (2), STADA (4), YSS Laboratories (5), Zuventus (4 and Eurofarma (2)). No significant variations in zones of inhibition (±1 mm) were observed between generic pip-tazo and branded product. Six dates USA 1.0-1.25 µg/ml). S. aureus (ATCC 25922, 1.75-2.0 µg/ml, P. aeruginosa (ATCC 27853, 2.0-2.5 µg/ml), and E. coli (ATCC 29213, 3.0-3.5 µg/ml) were used to screen the generic P/T products. The objective of the present study was to evaluate "non-branded" generic pip/tazo products for antimicrobial potency against four selected assay organisms (replicate testing and directly compare them to the current Zosyn® formulation purchased from a drug distributor in the USA. 2.0-2.5 µg/ml, 3.0-3.5 µg/ml, and 1.25-1.5 µg/ml). Determination of the MIC value was used for calculation of the potency test lot compared to the Zosyn® (Wyeth pharmaceutical knockout panel IMCA, Wayne, PA: CLSI. M100-S18, accessed February 2008).